Recombinant luteinizing hormone (rLH) for ovarian hyperstimulation

Co-administration of recombinant luteinizing hormone (rLH) to rFSH in GnRH agonist down-regulated women does not result in more live births than controlled ovarian hyperstimulation with rFSH alone.

A Cochrane review included 14 studies with a total of 2612 subjects. Eleven trials involving 2396 women used a GnRH agonist. There was no evidence of a statistical difference in live birth rate reported in two trials (OR 1.51, 95% CI 0.79 to 2.87). There was no evidence of a statistical difference in clinical pregnancy rates reported in seven trials OR 1.15, 95% CI 0.91 to 1.45. There was no evidence of a statistical difference or in ongoing pregnancy rates seven trials OR 1.22, 95% CI 0.95 to 1.56. Three trials used a GnRH antagonist. No data on live birth rates was available. There was no evidence of a statistical difference in clinical pregnancy rates (one trial: OR 0.79, 95% CI 0.26 to 2.43) or in ongoing pregnancy rates (two trials: OR 0.83, 95% CI 0.39 to 1.80) comparing both groups. The pooled pregnancy estimates of trials including only poor responders showed significant increase in pregnancy rate, in favour of co-administrating rLH (three trials: OR 1.85, 95% CI 1.10 to 3.11).

Ədəbiyyat

1. Mochtar MH, Van der Veen, Ziech M, van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007 Apr 18;(2):CD005070.